Madrigal Pharmaceuticals (MDGL) PT Raised to $709 at Truist Securities

May 13, 2026 6:16 AM

Truist Securities analyst Srikripa Devarakonda raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $709.00 (from $640.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found